MaxCyte Minutes Newsletter – Q2 2024

Welcome to the second edition of the MaxCyte Minutes for 2024!

At MaxCyte, we know that cells are precious, especially when they are the key to novel treatments for patients in need. In this issue of the MaxCyte Minutes newsletter, we share some news, events and technical content highlighting how we can help you with your next cell engineering project to preserve those precious cells and accelerate your research from concept to clinic and commercialization.

In the news

Icon stating "in the news"

MaxCyte Signs a Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

MaxCyte is thrilled to announce that we are partnering with Be Biopharma (BeBio), a company pioneering the development of engineered B cell medicines (BCMs) to dramatically improve the lives of patients who are living with cancer, rare diseases and other serious conditions.

“Our technology and expertise will empower BeBio to unlock the potential of human B cells to address the unmet medical needs of patients with genetic diseases, cancer, and beyond. This new class of therapies could be transformative, and we are excited to be part of this journey,” said Maher Masoud, President and CEO of MaxCyte.

Icon stating "in the news"

MaxCyte Signs a Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

MaxCyte is excited to announce we have signed a new strategic platform license with Legend Biotech, a fully integrated cell therapy company with expertise in developing advanced cell therapies across diverse technology platforms.

“As a leading provider of cell-engineered platform technologies for drug developers, our global infrastructure allows us to provide Legend Biotech with technical, scientific, and regulatory support to advance its non-viral engineered therapeutic pipeline across all major regions,” said Maher Masoud, President and CEO of MaxCyte.

Logo of Biocompare

The State of Cell and Gene Therapies for Cancer Treatment

James Brady, PhD, Senior Vice President, Technical Applications and Customer Support at MaxCyte, spoke with biocompare about non-viral approaches for CAR-T engineering for cancer treatment. “We are seeing people use CRISPR-based approaches to knock out checkpoint inhibitors, endogenous T-cell receptors, HLA molecules to enable the development of allogeneic therapies, and tumor antigens to prevent fratricide,” said James.

MaxCyte is proud to support such research with our Flow Electroporation® technology, working to bring faster, cheaper, and less invasive development of cell therapies for cancer. “Our goal is to get more therapies to patients more quickly, to improve the lives of cancer patients,” shares James.

Cell and gene therapy

New eBook - Unlocking the Code: Insights into Genetic Disease Therapy

Gain an understanding of the role of electroporation in the development of genetic disease therapies with our latest eBook, Exploring Electroporation 2: Genetic Diseases. This second eBook highlights MaxCyte's contribution to genomic medicine through our cutting-edge technology. Discover how MaxCyte electroporation enables CRISPR-Cas9 delivery and gene correction for monogenetic disorders and complex conditions. Our technology is setting new benchmarks for both discovery and clinical research.

Get your copy today and join us in the evolution of genomic medicine.

New eBook - Explore how MaxCyte’s Flow Electroporation technology has helped scientists advance their iPSC research

Induced pluripotent stem cells (iPSCs) have tremendous potential to transform human health. Their unique ability to differentiate into any cell type is important for disease modeling and both personalized and allogeneic regenerative medicine.

Electroporation is a highly efficient non-viral cell engineering method that preserves cell viability, while saving time and reducing costs. We are proud to collaborate with leading researchers and innovators, working hand-in-hand to develop the next generation of stem cell therapies and disease models.

Explore how MaxCyte’s flow electroporation technology has helped scientists advance their IPSC research.

Conference recap

The MaxCyte team standing in front of the MaxCyte booth at the 2024 ASGCT annual meeting

MaxCyte stands out at the 2024 American Society of Gene and Cell Therapy annual meeting

This year’s American Society of Gene and Cell Therapy (ASGCT) annual meeting was fantastic! We enjoyed meeting with so many peers and researchers. The excitement within the cell and gene therapy research community was palpable as we learned about the new therapies and potential cures that are advancing to the clinic.

MaxCyte hosted a panel discussion and presented multiple posters. We want to share some of these with you in case you couldn't make those sessions or attend the conference.

Photo of Lauren Unsworth

Non-Viral Cell Engineering of Peripheral Blood Natural Killer Cells Using a GMP-Compliant, Scalable Electroporation Platform

Our MaxCyte scientist, Lauren Unsworth, gives a ten-minute presentation of her poster from the 2024 ASGCT annual meeting.

Headshot of Isabel Daher

Efficient Scalable Manufacturing of Virus-like Particles for the Delivery of CRISPR-Cas9 Ribonucleoproteins using a cGMP-Compliant Electroporation Platform

Our MaxCyte scientist, Isabel Daher, gives a six-minute presentation of her poster from the 2024 ASGCT annual meeting.

Photograph of Ben Askin

Streamlining the CRISPR Editing Process in an eTIL Cell Therapy

Ben Askin, Scientist, Cellular Process Development at KSQ Therapeutics, presents a nine-minute presentation of KSQ Therapeutics' work developing a scalable cGMP process for their engineered tumor-infiltrating lymphocyte (eTIL™) cell therapy.


American Pharmaceutical Review logo

Advances in Electroporation Technology: Cell and Gene Therapy Development Innovations

Listen to this podcast discussing MaxCyte's role in the cell and gene therapy market and how we have evolved to meet the changing needs and demands of this industry as well as innovations for the future.

Presenters: Mike Auerbach, Editor-In-Chief at American Pharmaceutical Review, and Debra Barberini, PhD, Business Development Manager at MaxCyte

Case study

Andrew Mancini

From Roadblocks to Breakthroughs, Unlocking Clinic-Ready Efficiency

Andrew shares how his collaboration with a cell-therapy developer led to a 90% efficiency boost, enabling the developer to confidently proceed with clinical manufacturing


Focus on

Headshot of yuqi zhu

Interview with Yuqi Zhu, Senior Scientist, Cell Therapy Process Development, at MaxCyte

Yuqi Zhu, a Senior Scientist at MaxCyte, shares her journey and motivations to work in the exciting biotech industry. She shares what she is most proud of in her work. "At MaxCyte, we are trying our best to change the way that companies are discovering and developing drugs. Because of my mother’s experience, I know that the right medicines can make a difference in the lives of patients," shares Yuqi.

Upcoming events

We are excited to attend multiple conferences and host many institutional seminars and events. Find all the latest on our Events page.